Agonistic Properties of a Series of Psychotropic Drugs at 5-HT Receptors in Rat and Human Brain Membranes Determined by [S]GTPγS Binding Assay

Overview

Journal Pharmacol Rep

Specialty Pharmacology

Date 2023 Jan 13

PMID 36637685

Authors

Yuji Odagaki

Masaki Mikami

Masakazu Kinoshita

J Javier Meana

Luis F Callado

Jesus A Garcia-Sevilla

Dasiel Oscar Borroto-Escuela

Kjell Fuxe

Affiliations

Soon will be listed here.

Abstract

Background: Many psychoactive compounds have been developed to have more beneficial clinical efficacy than conventional drugs by adding agonistic action at 5-HT receptors. The aim of the present study was to evaluate several psychotropic drugs that had been reported to behave as an agonist at 5-HT receptor (aripiprazole, brexpiprazole, asenapine, lurasidone, and vortioxetine) in both rat and postmortem human brain membranes.

Methods: The [S]GTPγS binding assay for G proteins coupled with 5-HT receptors was performed in rat brain membranes and postmortem human brain membranes.

Results: The specific binding was stimulated by brexpiprazole in rat hippocampus, human hippocampus, and human prefrontal cortex. Aripiprazole also behaved as an agonist in the same brain regions. Interestingly, its potency was much higher in rat hippocampal membranes than in human brain membranes, indicating the possibility of species differences. Although vortioxetine was an efficacious stimulator at high concentrations, its potency was undeterminable because of a lack of saturability. In addition to 5-HT receptor agonism, involvement of other components, e.g., 5-HT receptor agonism, was speculated by the biphasic inhibitory effects of the selective 5-HT receptor neutral antagonist. Negligible stimulatory effects were obtained as to lurasidone and asenapine.

Conclusions: Our previous studies have raised the concept of a psychoactive drug group with a common pharmacological mechanism of action, i.e., 5-HT receptor agonism, consisting of perospirone, aripiprazole, ziprasidone, clozapine, quetiapine, nemonapride, and trazodone. The present study demonstrates the data indicating that brexpiprazole and probably vortioxetine are included in this drug group. Lurasidone and asenapine are excluded from this group.

References

Berger M, Gray J, Roth B . The expanded biology of serotonin. Annu Rev Med. 2009; 60:355-66. PMC: 5864293. DOI: 10.1146/annurev.med.60.042307.110802. View

Charnay Y, Leger L . Brain serotonergic circuitries. Dialogues Clin Neurosci. 2011; 12(4):471-87. PMC: 3181988. View

Barnes N, Ahern G, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S . International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacol Rev. 2020; 73(1):310-520. PMC: 7770494. DOI: 10.1124/pr.118.015552. View

Akimova E, Lanzenberger R, Kasper S . The serotonin-1A receptor in anxiety disorders. Biol Psychiatry. 2009; 66(7):627-35. DOI: 10.1016/j.biopsych.2009.03.012. View

Kaufman J, DeLorenzo C, Choudhury S, Parsey R . The 5-HT1A receptor in Major Depressive Disorder. Eur Neuropsychopharmacol. 2016; 26(3):397-410. PMC: 5192019. DOI: 10.1016/j.euroneuro.2015.12.039. View

Bantick R, Deakin J, Grasby P . The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?. J Psychopharmacol. 2001; 15(1):37-46. DOI: 10.1177/026988110101500108. View

Millan M . Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther. 2000; 295(3):853-61. View

Albert P, Vahid-Ansari F . The 5-HT1A receptor: Signaling to behavior. Biochimie. 2019; 161:34-45. DOI: 10.1016/j.biochi.2018.10.015. View

Polter A, Li X . 5-HT1A receptor-regulated signal transduction pathways in brain. Cell Signal. 2010; 22(10):1406-12. PMC: 2903656. DOI: 10.1016/j.cellsig.2010.03.019. View

10.

Loane C, Politis M . Buspirone: what is it all about?. Brain Res. 2012; 1461:111-8. DOI: 10.1016/j.brainres.2012.04.032. View

11.

Newman-Tancredi A . The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs. 2010; 11(7):802-12. View

12.

Kenakin T . New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. Br J Pharmacol. 2012; 168(3):554-75. PMC: 3579279. DOI: 10.1111/j.1476-5381.2012.02223.x. View

13.

Odagaki Y, Toyoshima R . 5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes. Clin Exp Pharmacol Physiol. 2007; 34(5-6):462-6. DOI: 10.1111/j.1440-1681.2007.04595.x. View

14.

Odagaki Y, Toyoshima R, Yamauchi T . Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005; 19(3):235-41. DOI: 10.1177/0269881105051526. View

15.

Bagdy G . Serotonin, anxiety, and stress hormones. Focus on 5-HT receptor subtypes, species and gender differences. Ann N Y Acad Sci. 1998; 851:357-63. DOI: 10.1111/j.1749-6632.1998.tb09009.x. View

16.

Odagaki Y, Toyoshima R . Detailed pharmacological characterization of 5-HT1A-receptor-mediated [35S]GTP gamma S binding in rat hippocampal membranes. J Pharmacol Sci. 2005; 98(1):66-76. DOI: 10.1254/jphs.fpj05010x. View

17.

Odagaki Y, Toyoshima R . 5-HT1A receptor-mediated G protein activation assessed by [35S]GTPgammaS binding in rat cerebral cortex. Eur J Pharmacol. 2005; 521(1-3):49-58. DOI: 10.1016/j.ejphar.2005.07.018. View

18.

Odagaki Y, Kinoshita M, Ota T, Meana J, Callado L, Garcia-Sevilla J . Optimization and pharmacological characterization of receptor-mediated G activation in postmortem human prefrontal cortex. Basic Clin Pharmacol Toxicol. 2018; 124(6):649-659. DOI: 10.1111/bcpt.13183. View

19.

Strange P . Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors. Br J Pharmacol. 2010; 161(6):1238-49. PMC: 3000650. DOI: 10.1111/j.1476-5381.2010.00963.x. View

20.

Price G, Roberts C, Watson J, Burton M, Mulholland K, Middlemiss D . Species differences in 5-HT autoreceptors. Behav Brain Res. 1996; 73(1-2):79-82. DOI: 10.1016/0166-4328(96)00074-5. View